Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging

Investigative Radiology

Volumn 45, Issue 5, 2010, Pages 233-244

  Liang, Jiachao ^a   Sammet, Steffen ^a   Yang, Xiangyu ^a   Jia, Guang ^a   Takayama, Yukihisa ^a   Knopp, Michael V ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

7T; Contrast agent; Crossover comparison; DCE MRI; Gadobenate dimeglumine

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; PENTETIC ACID;

ARTICLE; IMAGING SYSTEM; IN VIVO STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

EID: 77951126844     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181d54507     Document Type: Article

References (49)

1. Burns M. The U.S. market for medical imaging contrast media. Las Vegas NV: Bio-tech Systems Inc; 2004.
2. Lin SP, Brown JJ. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging. 2007;25:884-899.
3. Bellin MF, van der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol. 2008;66:160-167.
4. Runge VM. Contrast media research. Invest Radiol. 1999;34:785-790.
5. Bellin MF. MR contrast agents, the old and the new. Eur J Radiol. 2006;60: 314-323.
6. Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging. 1999;10:260-266.
7. Knopp MV, Tengg-Kobligk H, Choyke PL. Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol Cancer Ther. 2003;2:419-426.
8. Essig M. MR imaging of CNS tumors: are all contrast agents created the same? Neuroradiology. 2006;48(suppl 1):3-8.
9. Runge VM, Biswas J, Wintersperger BJ, et al. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging\comparison to 1.5 tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol. 2006;41:244-248.
10. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2004;230:55-64.
11. Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol. 1999;6:282-291.
12. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol. 1998;33:798-809.
13. Colosimo C, Demaerel P, Tortori-Donati P, et al. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children. Pediatr Radiol. 2005;35:501-510.
14. Runge VM, Parker JR, Donovan M. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol. 2002;37:269-280.
15. Knopp MV, Schoenberg SO, Rehm C, et al. Assessment of gadobenate dimeglumine for magnetic resonance angiography: phase I studies. Invest Radiol. 2002;37:706-715.
16. Schneider G, Maas R, Schultze KL, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol. 2003;38:85-94. (Pubitemid 36125892)
17. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins\a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-796.
18. de Haen C, La Ferla R, Maggioni F. Gadobenate dimeglumine 0.5 M solution for injection (Multihance) as contrast agent for magnetic resonance imaging of the liver: mechanistic studies in animals. J Comput Assist Tomogr 1999; 23(suppl 1):S169-S179. (Pubitemid 30027606)
19. Heywang SH, Hahn D, Schmidt H, et al. MR imaging of the breast using gadolinium-DTPA. J Comput Assist Tomogr. 1986;10:199-204.
20. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med. 1991;17:357-367.
21. Brix G, Semmler W, Port R, et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr. 1991;15:621-628.
22. Sardanelli F, Fausto A, Esseridou A, et al. Gadobenate dimeglumine as a contrast agent for dynamic breast magnetic resonance imaging: effect of higher initial enhancement thresholds on diagnostic performance. Invest Radiol. 2008;43:236-242.
23. van der Molen AJ, Bellin MF. Extracellular gadolinium-based contrast media: differences in diagnostic efficacy. Eur J Radiol. 2008;66:168-174.
24. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol. 2006;24:3293-3298. (Pubitemid 46622069)
25. Yuh WT, Mayr NA, Jarjoura D, et al. Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer. Invest Radiol. 2009;44:343-350.
26. Yankeelov TE, Luci JJ, Lepage M, et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging. 2005;23:519-529.
27. Lowry M, Zelhof B, Liney GP, et al. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacoki-netic models in the discrimination of malignant from normal tissue. Invest Radiol. 2009;44:577-584.
28. Turetschek K, Preda A, Novikov V, et al. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging. 2004;20:138-144.
29. de Lussanet QG, Langereis S, Beets-Tan RG, et al. Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology. 2005;235:65-72.
30. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 1997;7:91-101.
31. Hoffmann U, Brix G, Knopp MV, et al. Pharmacokinetic mapping of the breast\a new method for dynamic MR mammography. Magn Reson Med. 1995;33:506-514.
32. Yang XY, Liang JC, Heverhagen JT, et al. Improving the pharmacokinetic parameter measurement in dynamic contrast-enhanced MRI by use of the arterial input function: theory and clinical application. Magn Reson Med. 2008;59:1448-1456.
33. Nakada T. Clinical application of high and ultra high-field MRI. Brain Dev. 2007;29:325-335.
34. Brantzawadzki M, Norman D, Newton TH, et al. Magnetic-resonance of the brain\the optimal screening technique. Radiology. 1984;152:71-77.
35. Schneider G, Kirchin MA, Pirovano G, et al. Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging. 2001;14: 525-539.
36. Gasperini C, Paolillo A, Rovaris M, et al. A comparison of the sensitivity of MRI after double-and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. Magn Reson Imaging. 2000;18:761-763.
37. Erickson BJ, Campeau NG, Schreiner SA, et al. Triple-dose contrast/magnetization transfer suppressed imaging of "non-enhancing" brain gliomas. J Neurooncol. 2002;60:25-29.
38. Henkelman RM. Measurement of signal intensities in the presence of noise in MR images. Med Phys. 1985;12:232-233.
39. McAuliffe MJ, Lalonde F, McGarry DP, et al. Medical image processing, analysis & visualization in clinical research. In: IEEE Symposium on Computer-Based Medical Systems (CBMS 2001). Bethesda, MD: 2008:381-386.
40. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging. 1999;10:254-259.
41. Sherif H, Mahfouz AE, Oellinger H, et al. Peripheral washout sign on contrast-enhanced MR images of the breast. Radiology. 1997;205:209-213.
42. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of Gadopentetate Dime-glumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (Multihance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;41:213-221.
43. Spinazzi A, Lorusso V, Pirovano G, et al. Multihance clinical pharmacology: biodistribution and MR enhancement the liver. Acad Radiol. 1998;5:S86-S89.
44. Weinmann HJ, Ebert W, Misselwitz B, et al. Tissue-specific MR contrast agents. Eur J Radiol. 2003;46:33-44.
45. Planchamp C, Gex-Fabry M, Dornier C, et al. Gd-BOPTA transport into rat hepatocytes: pharmacokinetic analysis of dynamic magnetic resonance images using a hollow-fiber bioreactor. Invest Radiol. 2004;39:506-515.
46. Port M, Corot C, Violas X, et al. How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: the concept of dynamic relaxivity. Invest Radiol. 2005;40:565-573.
47. Haacke EM, Tkach JA. Fast MR-imaging\techniques and clinical- applications. Am J Roentgenol. 1990;155:951-964.
48. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223-232.
49. Donahue KM, Burstein D, Manning WJ, et al. Studies of Gd-Dtpa relaxivity and proton-exchange rates in tissue. Magn Reson Med. 1994;32:66-76.